

# Neurotech

12 November 2020

## Quarterly Report for the period ended 30 September 2020 – Additional Information

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company") provides the following additional information pursuant to Listing Rule 4.7C to complement its Quarterly Activities report and Appendix 4C dated 30 October 2020.

As noted in its Appendix 4C, during the quarter the Company expended a gross total, excluding revenue sources, of \$437,000 on the operations of the Company. This was made up of research and development (\$102,000), product manufacturing (\$21,000), advertising and marketing (\$6,000), staff costs (\$46,000), administrative and corporate costs (\$125,000) along with payments for investments of (\$70,000), repayment of borrowings (\$18,000) and equity issue costs (\$49,000).

Further, payments to related parties and their associates as detailed in Section 6 of the Appendix 4C are Payments for director fees (\$11,129) and corporate services, accounting and company secretarial fees (\$37,298).

### Authority

This announcement has been authorised for release by Winton Willesee.

### Further Information

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 (0)41 066 7844

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on facilitating the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism. Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

---

#### Neurotech International Ltd

ABN 73 610 205 402

Suite 5 CPC, 145 Stirling Highway

Nedlands, Western Australia 6009

[www.neurotechinternational.com](http://www.neurotechinternational.com)